Objective: To assess the effects of a comprehensive change in dietary composition on endogenous hormone metabolism. The specific aim was to examine whether this intervention could lead to favourable changes in insulin sensitivity, levels of IGF-I and IGF-binding proteins (IGFBPs), and total and bioavailable testosterone and estradiol, that would be expected to reduce breast cancer risk. Design: Randomised dietary intervention study; duration of 5 months. Subjects: From a total of 99 postmenopausal women, who had elevated baseline plasma testosterone levels, 49 women were randomly assigned to the dietary intervention arm and the other 50 to a control group. Interventions: Main aspects of the dietary intervention were reductions in the intake of total fat and refined carbohydrates, an increase in the ratio of n-3 over n-6 plus saturated fatty acids, and increased intakes of foods rich in dietary fibre and phytooestrogens. Results: Relative to the control group, women of the intervention group showed a significant reduction of body weight, waist circumference, fasting serum levels of testosterone, C peptide, glucose, and insulin area after glucose tolerance test, and a significant increase of serum levels of sex hormone-binding globulin, IGFBP-1, -2, and growth hormone-binding protein. Serum levels of IGF-I did not change. Conclusion: This comprehensive dietary intervention strategy proved to be successful in inducing changes in endogenous hormone metabolism that might eventually result in reduced breast cancer risk. Additional studies are needed to show whether the dietary intervention and related hormonal changes can be both maintained over longer periods, of at least several years.
Introduction
Recent epidemiological studies have provided evidence that comparatively elevated plasma levels of IGF-I, either as absolute concentrations or relative to levels of IGFBP-3, IGF's major plasmatic binding protein, are related to an increased risk of breast cancer (Hankinson et al, 1998; Toniolo et al, 2000) . Other studies have shown similar associations of plasma IGF-I levels with the risk of developing cancers of the prostate (Chan et al, 1998; Stattin et al, 2000) or colorectum (Giovannucci et al, 2000; Palmqvist et al, 2002) , and ovary (Kaaks & Lukanova, 2001; Lukanova et al, 2002) . In addition to these epidemiological relations, there is extensive experimental evidence that IGF-I can enhance tumour development by stimulating cell proliferation, by inhibiting programmed cell death (apoptosis), and by affecting the degree of cellular differentiation (Khandwala et al, 2000) .
IGF-I and at least six different IGF-binding proteins (IGFBPs) are synthesised in the liver, which is the origin of more than 80% of these peptides in blood. Circulating IGF-I can thus be considered a classical hormone, exerting endocrine effects on other target tissues than that in which it was produced. The IGFBPs regulate the size of the IGF-I pool in blood and the efflux of IGF-I from blood to target tissues. Besides the liver, IGF-I and IGFBPs are also synthesised by most other tissue types, where the peptides exert paracrine and autocrine effects (Jones & Clemmons, 1995) .
One key function of IGF-I is the stimulation of anabolic processes and body growth. In addition, IGF-I, and also insulin, have a central role in regulating plasma levels of bioavailable sex steroids. In vitro, IGF-I and insulin both inhibit the synthesis of sex hormone-binding globulin (SHBG) by liver, and stimulate the synthesis of androgens in ovarian and adrenal tissues (Kaaks, 1996; Poretsky et al, 1999) . Plasma levels of both insulin and IGF-I generally correlate inversely with levels of SHBG, in both men and women (Pugeat et al, 1991) . In women with ovarian hyperandrogenism (polycystic ovary syndrome), plasma levels of insulin correlate directly with levels of D4-androstenedione (D4A), total testosterone (T), and free testosterone (fT) unbound to SHBG or albumin (Kaaks, 1996; Poretsky et al, 1999) . Circulating levels of both insulin and IGF-I are regulated as a function of available energy and nutrients essential for growth (eg, amino acids, calcium), from the diet, or from body reserves (Thissen et al, 1994) , and elevated levels of insulin and/or IGF-I might mediate effects of nutrition on plasma sex steroid profiles.
In this report, we present results from the Diet and Androgens (DIANA) study, a nutritional intervention study conducted among postmenopausal women that aimed at investigating the effects of a comprehensive change in diet on levels of endogenous hormones known to be related to breast cancer risk (Berrino et al, 2001a) . The intervention diet, consumed ad libitum, was designed to lower plasma insulin levels, by lowering the intake of total fat and foods rich in sugar and refined carbohydrates, by increasing the proportion of monounsaturated and n-3 polyunsaturated fatty acids, and by increasing the consumption of lowglycaemic index foods such as unrefined cereals, legumes, and vegetables. In addition, the diet was rich in phytooestrogens, both in the form of isoflavones and lignans, with the principal scope of reducing levels of endogenous androgens and oestrogens. The ultimate aim of this study was to determine whether this type of diet would be worth investigating in long-term trials to reduce the risk of breast cancer.
The effects of this intervention on plasma levels of SHBG, insulin, estradiol (E 2 ), and T were reported previously (Berrino et al, 2001b) . In the present report, we describe the effects on plasma levels of IGF-I, IGFBPs-1, -2 and -3, and growth hormone (GH), as well as of growth hormonebinding protein (GHBP), which is a marker of growth hormone receptor levels in liver and other tissues (Baumann, 2001 ). In addition, we examine the interrelations between levels of these peptides, and levels of SHBG and the sex steroids before and after the intervention.
Study subjects and methods

Subjects
In all, 312 healthy women, age 50-65 y, from the Milan area (northern Italy) volunteered to take part in the study after advertisements had been placed in the local media. Eligibility criteria were that women were postmenopausal for at least 2 y, had at least one ovary, did not use hormonal replacement therapy during the previous 6 months, had no history of cancer, did not follow a vegetarian, macrobiotic or other medically prescribed diet, and did not receive any treatment for diabetes.
Written informed consent was obtained from all the women and the Scientific and Ethical Committee of the Milan Cancer Institute approved the study.
Study design
The levels of T in the serum of the volunteers were determined (prebaseline), and the 104 women in the upper tertile (T40.38 ng/ml) were selected for the study. With the exception of two close friends, who were allocated to the same group, these women were individually randomised to the intervention and control groups (52 women each), stratified for age (above or under the median of 58 y), prebaseline serum T (three levels), and prebaseline fasting insulin (three levels). Women were selected on the basis of serum T level because its measurement is highly reliable , and it predicts breast cancer risk equally as well as serum oestrogen levels (Bouchard et al, 1993; Berrino et al, 1996) . The women in the intervention group agreed to adhere to the diet described below for 4.5 months (between months 1 and 5 of the study). The control women were not given any information about this diet, nor any dietary instruction, but were advised to increase their consumption of fruit and vegetables according to the cancer prevention decalogue of the Europe Against Cancer program, a leaflet largely available to the general population.
Before the start and at the end of the intervention, fasting blood samples and 24-h urine samples were taken and stored at À301C for hormone assays. An oral glucose tolerance test was also performed, involving collection of blood samples 1, 2, and 3 h after the ingestion of 100 g of glucose.
Dietary intervention
Women in the intervention group were invited for common meals and cooking classes twice a week for 18 weeks. On each occasion, the menu was different, but mainly based on Mediterranean vegetarian and macrobiotic recipes. We recommended that the same foods should be consumed on a daily basis at home, but did not prescribe menus. However, we did provide written instructions that indicated how to replace meat, eggs, and dairy products by vegetable sources of essential amino acids, vitamins, and minerals; recommended that meat, eggs, and dairy products should not be eaten more than once a week; urged reducing the consumption of refined carbohydrates (sucrose, white bread, refined flour), replacing these by whole-grain cereal products, and using fruit or fermented cereal as edulcorants; and recommended cooking with little added fat and salt. The women were also encouraged to eat at least one portion of a soy product (soy milk, miso soup, tofu, tempeh, or soy beans) every day, to season moderately with unrefined olive oil and various seeds but not dairy fats, and to consume fish and seaweed. Every week each woman received a 1 kg loaf of bread made from whole-wheat flour and 8% flax seed (half whole seeds and half milled), occasionally mixed with oats or rye, and also a free pack of other recommended products that are not a normal part of the northern Italian diet. Additional details on the types of food consumed by the intervention and control groups have been given previously (Berrino et al, 2001b) .
In the first month of the study, participants were asked to change their habits gradually in order to prevent adverse reactions because of excessive fermentation in the bowel. The diet was ad libitum, and no advice was given to reduce total food intake or to count calories.
Assessment of dietary intake and anthropometric measurements
Before randomisation, all women compiled a food-frequency questionnaire developed for the European Prospective Investigation into Cancer and Nutrition (EPIC) (Pisani et al, 1997) . During the study, compliance with dietary recommendations was monitored by 24-h food-frequency diaries, which were filled in 24 times by the intervention group and 10 times by the control women. In the fourth month of the study, all women (ie, also those in the control group) were interviewed and asked to recall everything they had eaten in the preceding 24 h, including quantities. Data were collected with the computerised EPIC 24-h dietary recall system (Slimani et al, 2000) , which was then used to estimate absolute intakes of nutrients and energy in the two groups. The system makes use of the Italian food composition database (Salvini et al, 1998) , which also includes several foods used in macrobiotic recipes. The average consumption of isoflavonoids and lignans by the intervention and the control groups was estimated from available databases on the phytooestrogen content of foods (Polonsky et al, 1986; Mazur & Adlercreutz, 1988; Thompson et al, 1991; Eberhardt et al, 1994; Eidson et al, 1994; Whelan et al, 1994; Dawson et al, 1995; Reinli & Block, 1996; Nesbitt & Thompson, 1997; Wakai et al, 1999) and from the food-frequency diaries, using as standard portion sizes those derived from the interviews.
Height, weight, waist circumferences (at natural waist when clearly identifiable or midway between lower rib and iliac crest), and hip circumference (at crotch level) were measured at the beginning and at the end of the study.
Compliance, and subjects excluded from statistical analysis Of the 52 women of the intervention group, 50 followed the whole dietary programme. Two women followed only about half of the programme but, following the 'intention to treat' principle, were included in all the analyses. Only five women were absent more than five times from the 36 lessons and common meals. Urinary daidzein and equol levels were used as the indicator of compliance with soy consumption. Two women from the intervention group and one woman from the control group were excluded because they received hormonal drugs during the study period. Two other women from the control group were excluded because they did not attend the final examination. Thus, a total of 99 women were analysed: 50 in the intervention group, and 49 controls. Of these, four (two in the intervention group and two controls) had missing values for fasting insulin, and five (one in the intervention and four in the control group) had missing values for the oral glucose tolerance test.
Hormone assays
For insulin, samples were assayed within 2 weeks of collection. To reduce the effects of interassay variability, for SHBG, T, E 2 , IGF-I, IGFBP-1, -2, -3, GH, and GHBP, baseline and final serum samples of the same woman were analysed in the same batch. In each analytical batch, an equal number of samples from women of the intervention group and from women of the control group were measured. Laboratory personnel could not distinguish repeated samples belonging to the same subject, and were blind to their dietary status.
Radioimmunoassay (RIA) kits from ORION Diagnostic (Turku, Finland) for T and E 2 ; IRMA (immunoradiometric) kits from Farmos (Oulunsalo, Finland) for SHBG, and MEIA kits from ABBOTT (Abbott Park, IL, USA) for insulin were used. The coefficients of intra-and interassay variation in eight replicates were: 4.2 and 12.5% for a T value of 0.420 ng/ ml; 5.2 and 11.1% for an E 2 concentration of 10 pg/ml; 3.5 and 6.7% for an SHBG value of 34.0 nmol/l; and 2.5 and 4.6% for an insulin value of 14.2 mIU/ml.
IGF-I, IGFBP-1, IGFBP-3, and GH were measured by double-antibody IRMA kits. IGFBP-2 was measured by RIA, and GHBP by enzyme-linked immuno sorbent assay (ELISA). All the reagents were from Diagnostic System Laboratories (Webster, TX, USA). Total IGF-I was measured after acidethanol precipitation of IGFBPs. To control for the quality of these peptide measurements, three standard sera were inserted randomly in each batch. The mean intra-and interassay coefficients of variation were 1.5 and 3.4%, respectively, for IGF-I, 4.9 and 10.5% for IGFBP-1,10.8 and 16.0% for IGFBP-2, 1.5 and 5.1% for IGFBP-3, 4.3 and 8.7% for GH, and 7.2 and 8.9% for GHBP.
Free T (fT) and free E 2 (fE 2 ) were calculated from total serum T, E 2 , and SHBG using a set of theoretical equations based on the mass action laws, and validated for measurements of fT and fE 2 in serum samples of postmenopausal women. This set of equations relies on the evidence that interindividual variation in the concentrations of fT and fE 2 in blood is determined mainly by the interaction between SHBG, total T, and total E 2 , and that competitive binding of SHBG with other hormones in blood (eg, dihydrotestosterone) does not influence this equilibrium much (Vermeulen et al, 1999; Rinaldi et al, 2002) .
Statistical analyses
The statistical analysis focused on changes in hormonal and other relevant variables, calculated as the difference between end-of-study and baseline values for each woman. Hormone values were log transformed to obtain approximately normal frequency distributions, and effects of the intervention on hormone levels were examined as geometric mean differences. The statistical significance of mean changes in the intervention group compared to controls was assessed by analysis of variance (ANOVA) (using log-transformed variables for the various hormone and growth factor measurements). All ANOVAs were stratified according to the blocking (stratification) scheme used for the randomisation. As the numbers of observations within the various blocks were not balanced, all ANOVAs employed generalised linear models, using the SAS statistical software package. All P-values are for two-sided statistical tests.
Results
Changes in the dietary intake in the intervention group, as compared to the controls, have been described in detail previously (Berrino et al, 2001a) . In brief, 24-h recall data indicated that, towards the end of the 18-week intervention period, the total energy intake was about 250 kcal/day lower for the intervention group than for the control group. Women in the intervention group shifted from animal to vegetable sources of protein (animal proteins accounted for 29% of total protein against 60% in the control group) and fats (28% from animal sources against 43% in the control group), from simple to complex carbohydrates (34% of total carbohydrates from simple sugars against 44% among controls), and from low to high dietary fibre (35.5 against 23.3 g/day). Furthermore, a soy product was consumed on average 1.7 times a day, flax seeds (a very rich source of lignans) were eaten every day in bread or cookies, and seaweed (a source of lignans and n-3 fatty acids) was used every other day as an ingredient of various dishes. The women in the control group rarely, if ever, consumed any of these food items. The intervention group also increased their consumption of whole rice and cereal products, nuts and seeds, legumes, cruciferous vegetables and berries, and had significantly higher intakes of these foods than the control group. Other fruits and vegetables were consumed with equal frequencies by the intervention and control groups. The estimated intake of isoflavonoids in the intervention group was around 40 mg/day, against 2 mg/day for the control group. This large difference in estimated isoflavonoid intake was confirmed by measurements in a 24-h urinary sample collected at the end of the intervention period.
Between baseline (January: month 1) and the end of the 5-month intervention period (June: month 5), the dietary intervention group showed significant decreases in weight for the intervention group compared to the controls (À4.06 vs À0.56 kg), and concurrent changes in waist and hip circumferences (Table 1 ). In addition, the intervention led to significant decreases in plasma C-peptide, fasting glucose, and average area under the insulinaemic curve, and significant increases in IGFBP-1 and -2, compared to the control group (Table 2) . Plasma GH levels increased strongly (+54.2%) only in the intervention group but, as a result of the large interindividual variation in the measured GH levels (GH has a pulsatile daily secretion pattern), this increase was not statistically significant from changes among the control subjects. Levels of GHBP increased in the intervention group and decreased in the control group, and the difference between these changes in the two groups was statistically significant. The dietary intervention did not have any significant effect on levels of IGF-I and IGFBP-3. In addition to these results, we previously reported a significant increase in SHBG (+25%), and significant decreases in the intervention group of T (À18%) (Berrino et al, 2001b) . Serum E 2 levels showed an equal reduction, but this reduction was not statistically significant. Calculated levels of fT and fE 2 both decreased significantly in the intervention group, compared to the controls. After adjustment for changes in body weight and/or waist circumference, many of the effects of the dietary intervention were reduced, and no longer statistically significant. The changes in levels of fasting glucose and GHBP, however, remained statistically significant even after these adjustments. Table 3 shows Spearman's coefficients of correlation between anthropometric and hormonal variables at baseline (intervention and control groups combined), as well as between the longitudinal changes in these parameters over the intervention period (intervention group only). Indices of insulin resistance (fasting C-peptide, insulin, and areas under the glycaemic and insulinaemic curves after intake of the oral glucose dose) correlated strongly with BMI, waist circumference, and WHR, whereas each of these indices and anthropometric measurements correlated inversely with levels of IGFBP-1 and -2. Anthropometric indices of adiposity, as well as fasting insulin and glucose levels, correlated inversely with levels of GH, but not with IGF-I. Finally, each of the glycaemic and insulinaemic indices, as well as the anthropometric measures of adiposity, correlated directly with serum E 2 , fT, and fE 2 , and inversely with SHBG.
Longitudinally, and within the intervention group only, changes (in most subjects a decrease) in the anthropometric indices of adiposity (BMI, waist and hip circumferences, and WHR) all showed inverse correlations with changes in SHBG level (significantly so only for BMI). Furthermore, decreases in BMI, and waist and hip circumferences were associated with increases in SHBG, and with reductions in levels of total and bioavailable testosterone (again, significantly only for BMI), but not with changes in estradiol. There were no clear correlations between changes in insulin, C-peptide, or postload glycaemic and insulinaemic areas with changes in SHBG level, although changes in fasting insulin correlated directly with changes in free testosterone.
Discussion
This study shows multiple endocrine effects of a comprehensive dietary intervention, based on reduced intakes of refined carbohydrates and total fat, and increased intakes of n-3 fatty acids, dietary fibre, and phytooestrogens (both isoflavones and lignans). Major observations were reductions in fasting glucose, C-peptide, area under the insulinaemic curve, T and fT, and increases in IGFBP-1, IGFBP-2, SHBG and GHBP. In addition, there was a nonsignificant decrease in total E 2 and a nonsignificant increase in GH. The dietary intervention had no effect on serum levels of IGF-I and IGFBP-3.
The reductions in fasting glucose, (fasting) C-peptide, and insulin area most likely reflect improvements in insulin sensitivity. This improvement in insulin sensitivity appears to be explained, to a large extent, by the reductions in body weight and body fat stores, since the changes related to the intervention were no longer statistically significant after adjustment for changes in weight and/or waist circumference. Besides the decrease in body weight and fat stores, the reduced intake of refined carbohydrates and high-glycaemic index foods (Ludwig, 2002) and the relative increase in the intake of monounsaturated and n-3 fatty acids (Lovejoy, 1999) may also have contributed to the improvement in insulin sensitivity.
Energy restriction generally leads to increases in IGFBPs-1 and -2 (Thissen et al, 1994; Kaaks & Lukanova, 2001) , and this can be explained by concomitant reductions in insulin levels. Insulin is a key regulator of IGFBP-1 levels, inhibiting its synthesis by liver and other tissues (Brismar et al, 1995) , and plasma insulin generally correlates also inversely with circulating IGFBP-2 levels (Kaaks & Lukanova, 2001 ). These various relations were reflected in our data, which showed inverse cross-sectional correlations of IGFBP-1 and -2 with BMI, waist circumference measurements, and insulin, and increases in IGFBP-1 and -2 after the dietary intervention, in parallel with reductions in insulin levels. The increases in IGFBP-1 and -2 most likely caused a reduction in circulating free IGF-IFa small fraction of circulating IGF-I that is not bound by any IGF-binding protein, and that probably reflects the fraction most rapidly available to tissues for binding to cellular receptors. Other studies (Frystyk et al, 1995; Nam et al, 1997; Nyomba et al, 1997) have shown inverse correlations of plasma IGFBP-1 and -2 with plasma free IGF-I levels. Unfortunately, we had technical problems with an assay kit for measurement of free IGF-I, and thus All P-values are adjusted for treatment/intervention status, age class, insulin level, testosterone level. P-value weight: P-value for change in hormonal parameter with additional adjustment for change in weight. P-value waist: P-value for change in hormonal parameter with additional adjustment for change in waist circumference. P-value w wt: P-value for change in hormonal parameter with additional adjustment for changes in both weight and waist circumference.
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Insulin area fasting and glycaemic area fasting. Table 3 Cross-sectional and longitudinal relation (Spearman correlations) of indices of weight excess and of glucose and insulin metabolism with insulin-dependent binding proteins (IGFBP-1, IGFBP-2 and SHBG), total and bioavailable sex steroids, and GH/IGF-I axis could not reproduce these findings and quantify the change in free IGF-I. The principal stimulus for the synthesis of IGF-I (and also IGFBP-3) in liver and other tissues is provided by GH. However, the capacity of GH to stimulate IGF-I synthesis and to stimulate related growth processes depends strongly on the availability of energy and nutrients (eg, essential amino acids) from diet and body reserves. Reductions in IGF-I and IGFBP-3 generally observed with energy and/or protein restrictions can be explained by the resistance of liver and other tissues against the action of GH. This GH resistance is generally illustrated by a strong increase in circulating GH levels during energy restriction, in contrast to the drops in IGF-I and IGFBP-3 (Thissen et al, 1994; Kaaks & Lukanova, 2001) . Our data showed no drop in either IGF-I or IGFBP-3 in the dietary intervention group, but did show a 54% (but statistically nonsignificant) increase in serum GH levels. An alternative explanation for the rise in GH is a reduction in free IGF-I, which exerts negative feedback control over pituitary GH secretion (Tannenbaum et al, 1983; Chapman et al, 1998) .
Experimental studies with liver tissue in vitro (Baxter & Turtle, 1978; Tollet et al, 1990) , and clinical studies in diabetes patients (Hanaire-Broutin et al, 1996) have shown that insulin provides a key stimulus for GH-receptor synthesis. Furthermore, plasma GHBP is reduced in insulindependent diabetics (Mercado & Baumann, 1995; HanaireBroutin et al, 1996) , who have a strongly reduced endogenous production and hepatic exposure to insulin, but not in noninsulin-dependent diabetics, who generally have normal or even elevated endogenous insulin levels. GHBP is identical to the external domain of GH-receptors, and plasma GHBP in humans appears to originate mostly or entirely from the cleavage and release of this external domain into the circulation (Baumann, 2001 ). Contrary to these observations, however, and contrary to some previous intervention studies (Rasmussen et al, 1996) , our data did not show a decrease, but an increase, in GHBP with weight loss in the dietary intervention group. The absence in our data of a direct cross-sectional association of serum GHBP with BMI, however, is consistent with at least one other study in postmenopausal women (Bondanelli et al, 2001) .
Major changes in sex steroid metabolism were a significant decrease in serum T levels and an increase in SHBG. The strong rise in SHBG can be explained by the decrease in insulin, and possibly by a reduction of IGF-I activity within liver caused by the increase in IGFBP-1 and -2 levels. Studies with liver cells in vitro have clearly shown that insulin and IGF-I are both key regulators of SHBG synthesis (Singh et al, 1990; Crave et al, 1995) , and in cross-sectional human studies, both serum insulin and IGF-I generally have been found to be inversely correlated with SHBG level (Erfurth et al, 1996; Pfeilschifter et al, 1996) . Besides the inhibition of SHBG synthesis, insulin and IGF-I have both been shown to stimulate ovarian, and possibly adrenal, synthesis of androgen production (Kaaks, 1996; Poretsky et al, 1999) . The very significant drop in testosterone levels during the intervention may thus be explained by the reductions in insulin, and most likely in free IGF-I (through increases in IGFBP-1 and -2).
The effects of the dietary intervention on levels of IGFBP-1, -2, SHBG, T, and other endocrine parameters were stronger than one would have expected on the basis of cross-sectional relationships of these endocrine parameters with BMI, waist circumference, or fasting insulin. One possible explanation for this is that alterations in these hormone levels are stronger during the dynamic phase of weight loss or negative energy balance than alterations induced by a reduction in BMI per se. This would imply that some of the observed alterations in hormone levels would disappear when the dynamic phase of weight loss ends, and when body weight stabilises (even if stabilisation occurs at a lower than baseline value). Verification of this hypothesis would have required the collection of additional blood samples, at regular comparatively short intervals (eg, monthly) for some time after termination of the active intervention period; unfortunately, these additional samples were not available. Another possible explanation would be that, in addition to weight loss induced by the dietary intervention, there were other specific effects owing to the change in dietary composition on hormone metabolism. For example, the increase in dietary fibre may have led to higher faecal elimination of conjugated sex steroids excreted with bile into the gut (Goldin et al, 1982) .
If indeed the endocrine changes observed in this study were sustainable over a longer period of time, the dietary intervention used here might be of interest for future breast cancer prevention studies. Indeed, the change in total and bioavailable plasma T and E 2 in the intervention group was of roughly the same magnitude as the mean percentual differences observed between postmenopausal women who develop breast cancer, and control subjects who do not (The Endogenous Hormones and Breast Cancer Collaborative Group, 2002) . Additional hormonal changes that might also contribute to reduce breast cancer risk are the reduction in insulin, and increases in IGFBP-1 and -2 (which may reduce IGF-I bioactivity within the breast). Besides estradiol, IGF-I and insulin may exert direct growth-promoting effects on breast epithelium (Kaaks, 1996; Papa & Belfiore, 1996; Chappell et al, 2001; Lai et al, 2001) , and there is some evidence that both elevated circulating insulin (Bruning et al, 1992; Del Giudice et al, 1998; Yang et al, 2001 ) and elevated circulating free IGF-I (Li et al, 2001 ) may increase breast cancer risk, and worsen breast cancer prognosis (survival time) (Goodwin et al, 2002 ). An estimation of the breast cancer fraction that might be prevented with the type of diet examined in our study remains difficult, however, as favourable alterations in endogenous hormone levels relatively late in life may not have the same effect on risk as having had a more favourable hormone level lifetime. An intervention study with cancer as an end point (eg, in women at high genetic breast cancer risk) would be useful for this type of evaluation.
In conclusion, this study was conducted to examine the effects of a comprehensive, multifactorial change in diet, aiming at a maximum possible effect on hormones. The aim was to maximally combine different possible dietary intervention effects rather than to identify and disentangle the effects of specific, individual aspects of the diet. We observed a number of important changes in endogenous hormone metabolism after a comprehensive dietary intervention, and these changes (reductions in plasma insulin, T, and E 2 , and increases in SHBG, IGFBP-1, and IGFBP-2) were all in the direction anticipated, and would all be expected to contribute to a reduction in the risk of breast cancer (Kaaks, 1996) , as well as of other forms of cancer (Kaaks & Lukanova, 2001) , if it was possible to maintain the diet in the long term. Further studies are needed to examine whether the alterations in hormone levels would persist if the dietary intervention was continued for periods longer than 5 months.
